UNSPSC 51321804: Ciprofibrate

This classification denotes an anti-lipidemic agent with the molecular formula C13H14Cl2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8252JGO9S, chemically known as 2-(p-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic acid but generally known as ciprofibrate, which bears US NIH Compound Identifier 2763. European Medicines Agency schedules Ciprofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07469MIG. The term CIPROFIBRATE is an International Non-Proprietary Name.

UNSPSC 51321804 Ciprofibrate, a Commodity code, describes a specific pharmaceutical active ingredient but captures little of what state and local governments actually buy under pharmaceutical procurement codes today. Recent state and local opportunities tagged to this code show instead broad-based solicitations for advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs that span multiple drug classes and therapeutic categories well beyond a single active ingredient. State and local buyers procuring under this code include municipal fire and rescue departments (Tampa Fire Rescue via the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving state and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The Tampa Fire Rescue solicitation, for instance, requested four specific medication line items for emergency use rather than ciprofibrate alone, while the MMCAP RFP sought comprehensive catalogs of generic and OTC products from authorized wholesalers.

Geographic activity concentrates in Florida, Texas, and Minnesota based on recent postings. The City of Tampa issued an IFB (Bid No. 26-P-00188) for advanced life support medications with an April 8, 2026 deadline and an estimated contract value of $40,000, offering a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration's MMCAP office issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities, with contract effectiveness set for July 1, 2026, requiring vendors to maintain relationships with three authorized wholesalers and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in early April 2026 exploring direct-to-manufacturer prescription capabilities as a market intelligence tool ahead of formal procurement, indicating future solicitation activity but no immediate award opportunity.